Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck

$ 6.50

4.9 (262) In stock

Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) —dedicated to using leading-edge science to save and improve lives around the world. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge.

Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma - ScienceDirect

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry, Breast Cancer Research

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy - Reinisch - 2023 - Molecular Oncology - Wiley Online Library

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Cancers, Free Full-Text

Cancers, Free Full-Text

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance - Modern Pathology

Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials

Breast Masses (Breast Lumps) - Gynecology and Obstetrics - Merck Manuals Professional Edition